Compare GSK plc (GSK) vs Lemonade Inc (LMND) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Lemonade (LMND) trades at $64.675, down 7.79% over the past day, reflecting recent volatility. The stock shows a bullish technical signal with moving averages supporting upward momentum, while oscillators remain neutral. Fundamentally, revenue growth is robust, increasing from $257M in 2022 to $738M in 2025, but net losses persist, with a net income margin of -22.43% in 2025. Recent news highlights expansion into new states and reinsurance program improvements, driving investor interest despite profitability challenges.

The outlook for LMND is mixed; growth opportunities from AI-driven insurance expansion and state rollouts offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $69.60 price target, indicating limited near-term upside. Investors should weigh strong revenue trends against the path to profitability, with positive cash flow projected by 2026 being a key monitorable.